This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?
by Zacks Equity Research
EXEL's shares move north 25% in a month on the back of strong third-quarter results and raised outlook. We are optimistic about the stock as we believe there is room for growth.
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up
by Zacks Equity Research
Halozyme withdraws its proposal to acquire Evotec for 11 euro per share in cash. The company maintains its 2024 revenue guidance. Shares up.
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
by Zacks Equity Research
Here is how AnaptysBio, Inc. (ANAB) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
Corcept Shares Rise More Than 60% in Three Months: Here's Why
by Zacks Equity Research
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly.
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
by Zacks Equity Research
Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
by Zacks Equity Research
Puma Biotechnology starts the phase II ALISCA-Breast1 study on alisertib for treating hormone receptor-positive, HER2-negative metastatic breast cancer.
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
by Zacks Equity Research
Sage Therapeutics' pipeline setbacks continue as the phase II DIMENSION study on dalzanemdor for treating Huntington's disease fails to meet the primary goal.
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
by Zacks Equity Research
The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
by Zacks Equity Research
Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
by Zacks Equity Research
Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
by Zacks Equity Research
INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
by Zacks Equity Research
The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
by Zacks Equity Research
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.
Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma
by Zacks Equity Research
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant pleural mesothelioma.
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
by Zacks Equity Research
The European Commission approves ABBV's Elahere for the treatment of platinum-resistant ovarian cancer.
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
by Zacks Equity Research
The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
by Zacks Equity Research
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
RNA Stock Hits Record High on Entering the Cardiac Disease Space
by Zacks Equity Research
Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus
by Zacks Equity Research
FATE reports a narrower-than-expected loss on higher revenues for the third quarter of 2024. The company's innovative pipeline is in focus.
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
by Zacks Equity Research
AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
by Zacks Equity Research
SWTX reports mixed third-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut
by Zacks Equity Research
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, citing lower COVID-19 vaccine uptake.
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
by Zacks Equity Research
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised
by Zacks Equity Research
MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024. Stock rises in pre-market.
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus
by Zacks Equity Research
RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.